PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
August 3, 2023JAMA Oncology105 citationsOpen Access

Neoadjuvant Camrelizumab Plus Platinum-Based Chemotherapy vs Chemotherapy Alone for Chinese Patients With Resectable Stage IIIA or IIIB (T3N2) Non–Small Cell Lung Cancer

JLJie LeiJZJinbo ZhaoLGLi Gong

Key Points

Key points are not available for this paper at this time.

Abstract

ClinicalTrials.gov Identifier: NCT04338620.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Lei et al. (2023) studied this question.

synapsesocial.com/papers/69d962b77fca1f84ab684e9bhttps://doi.org/10.1001/jamaoncol.2023.2751
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Adebrelimab (SHR-1316) in Combination With Chemotherapy as Perioperative Treatment in Patients With Resectable Stage II to III NSCLCs: An Open-Label, Multicenter, Phase 1b Trial2022 · 34 citations
  2. 2Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group2008 · 2,705 citations
  3. 3Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data2014 · 888 citations
  4. 4Nivolumab + chemotherapy versus chemotherapy as neoadjuvant treatment for resectable stage IIIA NSCLC: Primary endpoint results of pathological complete response (pCR) from phase II NADIM II trial.2022 · 65 citations
  5. 5The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer2016 · 4,734 citations